share_log

恒瑞医药:HRS-5635注射液获批药物临床试验

Hengrui Pharmaceutical: HRS-5635 injection approved drug clinical trial

Breakings ·  Mar 28, 2023 15:37
Hengrui Pharmaceutical announced that its subsidiary Fujian Shengdi Pharmaceutical recently received approval from the China Drug Administration to issue the “Drug Clinical Trial Approval Notice” for HRS-5635 injection and will conduct clinical trials in the near future. HRS-5635 is a Class 1 innovative drug independently developed by the company. Non-clinical efficacy studies have shown that HRS-5635 shows excellent antiviral activity in all HBV genotypes and can exert an efficient and long-lasting antiviral effect in the body.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment